Li Q, Chen Z, Zhao Y, Li X, Pan H, Xia T
Sci Rep. 2015; 5:9587.
PMID: 25939860
PMC: 5386210.
DOI: 10.1038/srep09587.
Chen J, Zhu S, Xie X, Guo S, Tong L, Zhou S
J Huazhong Univ Sci Technolog Med Sci. 2013; 33(1):122-125.
PMID: 23392720
DOI: 10.1007/s11596-013-1083-1.
Damle N, Bal C, Bandopadhyaya G, Kumar L, Kumar P, Malhotra A
Jpn J Radiol. 2013; 31(4):262-9.
PMID: 23377765
DOI: 10.1007/s11604-013-0179-7.
Gennari A, Piccardo A, Altrinetti V, Corradengo D, Villavecchia G, De Censi A
Curr Oncol Rep. 2011; 14(1):20-6.
PMID: 22094933
DOI: 10.1007/s11912-011-0210-z.
Tamiya M, Suzuki H, Kobayashi M, Sasada S, Okamoto N, Morishita N
Med Oncol. 2011; 29(1):215-8.
PMID: 21258879
DOI: 10.1007/s12032-010-9801-z.
Metastatic pancreatic adenocarcinoma presenting as a large pelvic mass mimicking primary osteogenic sarcoma: a series of two patient cases.
Webber N, Sharma S, Grossmann A, Shaaban A, Jones K, Layfield L
J Clin Oncol. 2010; 28(29):e545-9.
PMID: 20713877
PMC: 2988643.
DOI: 10.1200/JCO.2010.28.6153.
Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients.
Karapanagiotou E, Terpos E, Dilana K, Alamara C, Gkiozos I, Polyzos A
Med Oncol. 2009; 27(2):332-8.
PMID: 19373566
DOI: 10.1007/s12032-009-9214-z.
Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic breast cancer of the axial skeleton: a comparative study.
Yilmaz M, Ozguroglu M, Mert D, Turna H, Demir G, Adaletli I
Med Oncol. 2007; 25(3):257-63.
PMID: 18040900
DOI: 10.1007/s12032-007-9027-x.
Bone metastases in breast cancer: higher prevalence of osteosclerotic lesions.
Quattrocchi C, Piciucchi S, Sammarra M, Santini D, Vincenzi B, Tonini G
Radiol Med. 2007; 112(7):1049-59.
PMID: 17952675
DOI: 10.1007/s11547-007-0205-x.
Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer.
Chung J, Park M, Kim Y, Chang J, Kim J, Kim S
Yonsei Med J. 2005; 46(3):388-93.
PMID: 15988811
PMC: 2815816.
DOI: 10.3349/ymj.2005.46.3.388.
Clinical surveillance for early stage breast cancer: an analysis of claims data.
Simon M, Stano M, Severson R, Hoff M, Smith D
Breast Cancer Res Treat. 1996; 40(2):119-28.
PMID: 8879678
DOI: 10.1007/BF01806207.
An analysis of the cost of clinical surveillance after primary therapy for women with early stage invasive breast cancer.
Simon M, Stano M, Hussein M, Hoff M, Smith D
Breast Cancer Res Treat. 1996; 37(1):39-48.
PMID: 8750526
DOI: 10.1007/BF01806630.
Breast cancer surveillance--a cost-effective strategy.
Schapira D
Breast Cancer Res Treat. 1993; 25(2):107-11.
PMID: 8347842
DOI: 10.1007/BF00662135.
An evaluation of clinical follow-up in women with early stage breast cancer among physician members of the American Society of Clinical Oncology.
Simon M, Hoff M, Hussein M, Martino S, Walt A
Breast Cancer Res Treat. 1993; 27(3):211-9.
PMID: 8312579
DOI: 10.1007/BF00665691.
Differentiation of malignant and degenerative bone lesions using dexamethasone interventional 3- and 24-hour bone scintigraphy.
Bhatnagar A, Mondal A, Kashyap R, Sharma R, Sharma R, CHAKRAVARTY S
Eur J Nucl Med. 1994; 21(7):609-14.
PMID: 7957346
DOI: 10.1007/BF00285582.
Bone metabolic markers in bone metastases.
Koizumi M, Yamada Y, Takiguchi T, Nomura E, Furukawa M, Kitahara T
J Cancer Res Clin Oncol. 1995; 121(9-10):542-8.
PMID: 7559734
DOI: 10.1007/BF01197767.
Identification of bone and liver metastases from breast cancer by measurement of plasma alkaline phosphatase isoenzyme activity.
Mayne P, Thakrar S, Rosalki S, Foo A, Parbhoo S
J Clin Pathol. 1987; 40(4):398-403.
PMID: 3584482
PMC: 1140971.
DOI: 10.1136/jcp.40.4.398.
Tests for detecting recurrent disease in the follow-up of patients with breast cancer.
Mansi J, Earl H, Powles T, Coombes R
Breast Cancer Res Treat. 1988; 11(3):249-54.
PMID: 3167230
DOI: 10.1007/BF01807283.
CA15-3: a reliable indicator of metastatic bone disease in breast cancer patients.
OBrien D, Horgan P, Gough D, Skehill R, Grimes H, Given H
Ann R Coll Surg Engl. 1992; 74(1):9-11; discussion 12.
PMID: 1736805
PMC: 2497470.